Related Experiment Videos
[Prostatic-vesical inflammation and sexual problems]
G F Menchini Fabris1, P Cilurzo
1Scuola di Specializzazione in Andrologia, Università degli Studi, Pisa.
Summary
Benign prostatic hyperplasia (BPH) can impact sexual health. Mepartricin treatment for BPH showed no adverse sexual effects and led to qualitative improvements in erectile activity.
Area of Science:
- Urology
- Andrology
- Pharmacology
Background:
- Benign prostatic hyperplasia (BPH) is a common condition in aging men.
- BPH is often associated with lower urinary tract symptoms and can affect sexual function.
- The relationship between prostatico-vesical inflammation and sexual disturbances requires further investigation.
Purpose of the Study:
- To investigate the relationship between prostatico-vesical inflammation and sexual disturbances in patients with BPH.
- To evaluate the efficacy and safety of mepartricin in treating BPH and its impact on sexual function.
Main Methods:
- Two groups of 15 patients with uncomplicated BPH were treated with mepartricin (150,000 U/day for 60 days).
- Group A had sexual disturbances, while Group B did not.
- Sexual function was assessed using symptomatic, instrumental, and a specific quantitative evaluation of dynamic erection.
Main Results:
- Mepartricin treatment confirmed the clinical implications of BPH on sexuality.
- Mepartricin demonstrated excellent manageability, with no drug-induced sexual disturbances observed.
- The erectile activity index showed qualitative improvement in both groups, even without quantitative changes.
Conclusions:
- BPH has significant clinical implications for male sexual health.
- Mepartricin is a well-tolerated medication for BPH with a positive impact on sexual function.
- Further research may explore the mechanisms behind mepartricin's qualitative improvement of erectile activity.